UK Court Upholds Watchdog's Finding on Excessive NHS Thyroid Drug Prices
(Reuters) -The Court of Appeal has upheld a British watchdog's 99 million pound ($131.94 million) fine against owners of Advanz Pharma for overcharging the National Health Service for essential thyroid drug liothyronine, the watchdog said on Thursday.
"In a unanimous judgment, the Court of Appeal has confirmed the Competition and Markets Authority's (CMA) finding of excessive and unfair pricing in the supply of liothyronine tablets in the UK," the CMA said.
($1 = 0.7504 pounds)
(Reporting by DhanushVignesh Babu in Bengaluru; Editing by Arun Koyyur)
Reuters Health Information © 2025 Reuters Ltd.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Motor 1
20 minutes ago
- Motor 1
VW's New EV Platform Still Supports Combustion Engines
It's been a little over four years since Volkswagen announced SSP, its all-encompassing electric vehicle architecture. The Scalable Systems Platform was originally expected to be ready by now, but it has been delayed until later this decade. Multiple reports from German media attributed the setback to VW's software division, Cariad. However, the automotive conglomerate is now ready to discuss SSP, and there's a surprise. Although SSP is primarily an electric platform, it will also support combustion engines. VW Group plans to introduce range extenders, with internal combustion engines functioning solely as generators to charge the battery. Like the BMW i3, Mazda's rotary MX-30 , and the upcoming Ramcharger, these engines won't have a mechanical link to the wheels. Nissan's e-Power technology follows a similar principle: the gasoline engine powers the battery, not the drivetrain. Photo by: Volkswagen Volkswagen had already indicated its interest in range extenders. Its newly established Scout brand will launch a pickup and an SUV equipped with naturally aspirated ICE generators . In China, the recently unveiled ID. Era concept previews a three-row SUV developed with SAIC, also featuring a gasoline-powered generator. SSP is a major initiative for VW. It will serve as the foundation for models across all its brands and will eventually replace all existing electric platforms. A teaser image shows five different body styles, ranging from a city hatchback to a large SUV. Automotive News reports that there will be eight derivatives in total, covering every segment of the market. Next-generation EVs based on SSP are expected to begin rolling out in 2026, likely debuting in China before arriving in Europe a year later. We may not see this technology in Europe, where VW CEO Thomas Schäfer believes plug-in hybrids are the more viable option. He told Autocar that range extenders are expensive to engineer, while today's plug-in hybrids already offer decent electric range and fast charging. According to Schäfer, offering both solutions wouldn't be economically feasible. Photo by: Volkswagen One of the most significant models to use the SSP platform will be the ninth-generation, electric-only Golf. It's scheduled to arrive near the end of the decade and will coexist with the combustion-engine Mk8 for several years. VW may keep the current Golf on sale until the mid-2030s . The electric Golf will be built in Wolfsburg, while production of the ICE model will move to the Puebla plant in Mexico in 2027. With SSP's key specifications now finalized, VW Group CEO Oliver Blume stated: 'We aim to be the global technology driver for the automotive industry. SSP will play a crucial role in this. We've reached an important milestone in developing our electric future platform. Now it's full steam ahead to implementation.' Catch Up With VW: Volkswagen Is Making Less Money Because It's Selling More EVs Volkswagen Could Give Ford More Reskinned Cars Get the best news, reviews, columns, and more delivered straight to your inbox, daily. back Sign up For more information, read our Privacy Policy and Terms of Use . Source: Volkswagen Group Share this Story Facebook X LinkedIn Flipboard Reddit WhatsApp E-Mail Got a tip for us? Email: tips@ Join the conversation ( )
Bloomberg
24 minutes ago
- Bloomberg
Boaz Weinstein Ready to Plow Billions More Into UK Trust Fight
Weeks after scoring a string of wins in his high-profile campaign for better returns from UK investment trusts, here is activist hedge fund manager Boaz Weinstein's latest message for the industry: I'm not going anywhere. 'I'm here and I'm ready to buy billions more of whatever is for sale and not effective,' Weinstein said in an interview. The comments come after he struck agreements with London-listed funds run by Janus Henderson Group Plc and Manulife Investment Management — two of the trusts he had campaigned against.
Associated Press
an hour ago
- Associated Press
Angle PLC Announces Board Changes
GUILDFORD, UNITED KINGDOM / ACCESS Newswire / June 6, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces that Non-Executive Director, Brian Howlett, has informed the Board that after 12 years of service he will be retiring at the Company's upcoming AGM. Separately, Non-Executive Director, Juliet Thompson has informed the Board of her resignation with immediate effect. The Company is reviewing the structure and composition for the Board moving forward. ANGLE Chairman, Jan Groen, commented: 'On behalf of the Board and the Company, we thank Brian for his advice and support over the last twelve years and offer our best wishes on his retirement. We also thank Juliet for her contributions to ANGLE over the last two and a half years and wish her well with her future endeavours.' For further information: ANGLE plc +44 (0) 1483 343434 Andrew Newland, Chief Executive Ian Griffiths, Finance Director Berenberg (NOMAD and Broker) Toby Flaux, Ciaran Walsh, Milo Bonser +44 (0) 20 3207 7800 FTI Consulting Simon Conway, Ciara Martin Matthew Ventimiglia (US) +44 (0) 203 727 1000 +1 (212) 850 5624 For Frequently Used Terms, please see the Company's website on Notes for editors About ANGLE plc ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected CTC harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis. ANGLE's commercial businesses are focusing on clinical services and diagnostic products. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma. Products include the Parsortix system, associated consumables and assays. Over 100 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit Any reference to regulatory authorizations such as FDA clearance, CE marking or UK MHRA registration shall be read in conjunction with the full intended use of the product: The Parsortix® PC1 system is an in vitro diagnostic device intended to enrich circulating tumor cells (CTCs) from peripheral blood collected in K2EDTA tubes from patients diagnosed with metastatic breast cancer. The system employs a microfluidic chamber (a Parsortix cell separation cassette) to capture cells of a certain size and deformability from the population of cells present in blood. The cells retained in the cassette are harvested by the Parsortix PC1 system for use in subsequent downstream assays. The end user is responsible for the validation of any downstream assay. The standalone device, as indicated, does not identify, enumerate or characterize CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs, including monitoring indications or as an aid in any disease management and/or treatment decisions. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit . SOURCE: ANGLE plc press release
